BRCA2 and familial pancreatic carcinoma: • Inhibits HR DNA repair and increases the formation of DSBs in combination with olaparib.• Enhances the sensitivity of pancreatic cancer cells to olaparib by inducing synthetic lethality to the functional BRCA2.IC50 = 20-30 μM